Category Archives: Business of Biotech

MDRNA patent allowance for siRNA

MDRNA, Inc. (NASDAQ: MRNA) announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application U.S. 11/624,630 covering an siRNA directed against a junctional adhesion molecule-1 (JAM-1) gene. The siRNA of the allowed claim has a broad array of potential applications, most notably as a therapeutic for the treatment of certain cancers, thrombosis, atherosclerosis, strokes, and hypertension; and enhances the delivery of drugs across the skin and the Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. complete merger

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) announced the completion of their merger. The combined company is named “Raptor Pharmaceutical Corp.” and will commence trading today on the NASDAQ Capital Market under the ticker symbol “RPTP.” Pursuant to NASDAQ’s regulations, for the first 20 trading days the ticker symbol will be “RPTPd”. The combined company will be headquartered in Novato, California and managed by Raptor’s existing management Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

LifeCycle Pharma announces Phase 2 results for liver transplant patients study

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

RegeneRx’s TB4 shows functional recovery in MS animal model

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis), according to Henry Ford Health System researchers. In addition, researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath). The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novelos announces $1 million NIH Grant

Novelos Therapeutics, Inc. (OTCBB: NVLT) was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) for a collaborative study with Massachusetts General Hospital (MGH) on two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury. This 17-month grant will fund the assessment of both drug candidates in animal models designed to reflect pulmonary injury resulting from, for example, a terrorist incident involving a radiation-dispersal device Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,